Posts by: Joana Carvalho, PhD

Joana Carvalho, PhD

Joana holds a BSc in Biology, a MSc in Evolutionary and Developmental Biology and a PhD in Biomedical Sciences from Universidade de Lisboa, Portugal. Her work has been focused on the impact of non-canonical Wnt signaling in the collective behavior of endothelial cells — cells that made up the lining of blood vessels — found in the umbilical cord of newborns.

July 6, 2020July 6, 2020

QuickFire Challenge Launched in Korea to Advance Healthcare Innovations

News

Janssen Korea and Johnson & Johnson Innovation have launched an initiative to help advance breakthrough innovations to improve patient care during the COVID-19 pandemic, including those that can potentially ... Read more

June 29, 2020June 29, 2020

Sotatercept Reduces Heart Strain, Improves Functional Capacity in PAH, Data Show

News, PAH News

Sotatercept (ACE-011) leads to clinically meaningful reductions in heart strain and improvements in functional capacity in patients with pulmonary arterial hypertension (PAH), top-line data from a Phase 2 trial ... Read more

June 12, 2020June 12, 2020

CAR Peptide Improves Remodulin Efficacy in PH Rat Model

News, PH News

CAR peptide (CAR), Vascular BioSciences’ lead therapeutic peptide candidate for pulmonary hypertension (PH) and other disorders, was found to increase the efficacy of Remodulin (treprostinil) at reducing clinical signs of ... Read more

June 5, 2020June 5, 2020

Bayer Offering Grants Up to $1M to Advance PAH, CTEPH Research and Care

CTEPH News, News, PAH News, PH News

Bayer has opened its second annual Pulmonary Hypertension Accelerated Bayer (PHAB) Awards, a grant funding program to support clinical research projects into pulmonary hypertension (PH), particularly those focused on pulmonary ... Read more

May 15, 2020May 15, 2020

Obesity Linked to Lower Risk of Mortality in PH Patients, Study Finds

News, PH News

Obesity is linked to a lower risk of mortality in patients with pulmonary hypertension (PH), particularly among those with precapillary PH, a study found. The study, “Obesity Is Associated ... Read more

May 6, 2020May 6, 2020

Opsumit Can Ease Strain on Right Ventricle and PAH Severity, Trial Shows

News

When given alone or in combination with other therapies, Opsumit (macitentan) leads to clinically meaningful improvements in right heart function in people with pulmonary arterial hypertension (PAH), according to ... Read more

April 23, 2020April 24, 2020

FDA Grants Orphan Drug Designation to Cereno Scientific’s Lead Candidate CS1 for PAH

News, PAH News

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to CS1, Cereno Scientific’s lead therapy candidate for the treatment of pulmonary arterial hypertension (PAH). CS1 is ... Read more

April 15, 2020April 15, 2020

FDA to Review Liquidia’s Application Requesting Approval of LIQ861 for PAH

News, PAH News

The U.S. Food and Drug Administration (FDA) has accepted for review the new drug application (NDA) Liquidia Technologies submitted earlier this year requesting marketing approval of LIQ861, its proprietary inhaled ... Read more

April 3, 2020April 3, 2020

Experts Issue Guidance on Use of Oral PPAs, Like Uptravi, in Treating PAH

News, PAH News, PH News

A consensus on the use of oral prostacyclin pathway agents (PPAs), like Uptravi (selexipag), as an add-on to standard therapies for certain types of pulmonary arterial hypertension (PAH) was ... Read more

January 8, 2020January 8, 2020

Review Recommends International Consensus be Reached on What Constitutes PH in Newborns

News, PH News

An international consensus is lacking about what constitutes pulmonary hypertension (PH) in newborns, according to a review study, which recommends the use of standardized criteria to define the disease ... Read more

Pin It on Pinterest